No results for ‘’
Godavari Drugs Ltd
₹101
(1%)
Tue, 25 Aug 2026, 10:07 pm
Health Technology
Pharmaceuticals: Major
24.5KGodavari Drugs EV/EBITDA Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 3.68 | 10.10 | 0 | 0 | 0 | 144.50 | 0 | 12.66 | 5.04 | 11.03 | 21.45 | 15.77 | 28.73 | 14.55 | 4.35 | 8.35 | 9.39 | 15.07 | 12.61 | 15.04 |
| Price to book ratio | 1.67 | 1.08 | 0.75 | 0.32 | 0.47 | 0.48 | 0.50 | 0.84 | 0.89 | 3.26 | 2.11 | 1.82 | 1.44 | 0.99 | 0.44 | 1.45 | 1.69 | 1.74 | 1.82 | 1.54 |
| Price to sales ratio | 4.71 | 2.67 | 1.81 | 0.80 | 0.98 | 0.83 | 0.97 | 0.80 | 0.84 | 0.73 | 0.41 | 0.38 | 0.37 | 0.21 | 0.09 | 0.28 | 0.31 | 0.36 | 0.45 | 0.58 |
| Price to cash flow ratio | 5.28 | 45.74 | 6.29 | 5.80 | 10.46 | 7.21 | 7.38 | 7.55 | 3.49 | 0 | 0 | 10.81 | 16.98 | 21.42 | 2.61 | 0 | 5.88 | 6.14 | 5.19 | 10.19 |
| Enterprise value | 20.1Cr | 14.51Cr | 9.25Cr | 4.92Cr | 5.73Cr | 5.54Cr | 5.57Cr | 8.22Cr | 9.79Cr | 48.43Cr | 43.78Cr | 43.38Cr | 40.36Cr | 38.12Cr | 34.87Cr | 63.27Cr | 70.05Cr | 89.8Cr | 125Cr | 128Cr |
| Enterprise value to EBITDA ratio | 0 | 536.11 | 36.96 | 6.66 | 6.60 | 5.43 | 0 | 3.99 | 4.26 | 7.95 | 9.69 | 8.25 | 9.99 | 6.96 | 5.78 | 6.44 | 6.17 | 7.37 | 9.21 | 10.43 |
| Debt to equity ratio | 0.92 | 0.41 | 0.23 | 0.21 | 0.17 | 0.15 | 0.29 | 0.33 | 0.27 | 0.69 | 1.13 | 1.01 | 1.10 | 1.25 | 1.40 | 1.28 | 0.79 | 1.09 | 1.50 | 1.50 |
| Return on equity % | 0 | 11.29 | -8.12 | -2.84 | -2.16 | 0.31 | -19.61 | 6.67 | 19.35 | 34.51 | 10.38 | 12.32 | 5.16 | 7.07 | 10.69 | 18.96 | 19.82 | 12.22 | 15.57 | 10.79 |
Godavari Drugs Ltd Enterprise Value to EBITDA Ratio
The Godavari Drugs Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Godavari Drugs Ltd's valuation, profitability, and overall financial performance. Tracking the Godavari Drugs Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Godavari Drugs Ltd (NSE: , BSE: 530317) is currently trading at ₹101, with a market capitalization of ₹102.29Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Godavari Drugs Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.
Godavari Drugs Ltd Enterprise Value to EBITDA Ratio Current Value
The current Godavari Drugs Ltd Enterprise Value to EBITDA Ratio stands at 10.43.
The latest Godavari Drugs Ltd Enterprise Value to EBITDA Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Godavari Drugs Ltd Enterprise Value to EBITDA Ratio Historical Trend
The Godavari Drugs Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:
- 2024: 10.43
- 2023: 9.21
- 2022: 7.37
- 2021: 6.17
- 2020: 6.44
The recent rise in Godavari Drugs Ltd Enterprise Value to EBITDA Ratio suggests strengthening valuation trends and improving market sentiment.
What Godavari Drugs Ltd Enterprise Value to EBITDA Ratio Indicates for Investors
The Godavari Drugs Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Godavari Drugs Ltd.
Godavari Drugs Ltd Enterprise Value to EBITDA Ratio Analysis Summary
The Godavari Drugs Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Godavari Drugs Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Godavari Drugs Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.